Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinoma

Abstract excerpt

Anti‑programmed death‑1 or anti‑programmed death‑ligand 1 (PD‑L1) blockade may be ineffective in some patients with non‑small cell lung cancer (NSCLC) with high percentage of tumor cells with PD‑L1 expression. In addition, immunotherapy may provide great benefits in patients without PD‑L1 expression. The present study assessed PD‑L1 protein expression by immunohistochemistry, copy number variation (CNV) of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Cancer Immunotherapy and Biomarkers